Related Experiment Videos
Management of Barrett's esophagus with high-grade dysplasia
Rodney J Pacifico1, Claude Deschamps, Kenneth K Wang
1Department of Internal Medicine, Division of Gastroenterology and Hepatology, Mayo Graduate School of Medicine, Main Alfred Gastroenterology Unit, St. Mary's Hospital, 1216 Second Street SW, Rochester, MN 55905, USA.
Abstract:
About 38% to 73% of patients diagnosed with BE with HGD and who went on to have an esophagectomy already had esophageal ACA. The low 5-year survival rate of invasive esophageal ACA places pressure on the physician to find a way to prevent or to remove the cancer. Endoscopic ablative therapies have been developed, but these new technologies are to be considered as a secondary option. Although there are many recent improvements in surveillance strategies and endoscopic ablative therapies, series are small and follow-up is short. These modalities do show promise and may be a good option in the future for patients who are poor surgical candidates. At the present time, the standard of care for BE with HGD in good surgical candidates is still esophagectomy.